Immunocompromised COVID-19 Patient Shed SARS-CoV-2 Up to 70 Days

Friday, Nov. 6, 2020 COVID-19 Patient Shed SARS-CoV-2 Up to 70 Days A COVID-19 patient whose immune system had been weakened by treatment for leukemia shed SARS-CoV-2 for up to 70 days, much longer than typical COVID-19 patients, NIAID scientists and colleagues report in Cell. SARS-CoV-2 is the virus that causes COVID-19. The finding could help inform treatment and testing considerations for COVID-19 patients with weakened immune systems National Institute of Allergy and Infectious Diseases  |  National Institutes of Health Update your subscriptions, modify your password or e-mail address, or stop subscriptions at any time on your Subscriber Preferences Page. You will need to use your e-mail address to log in. If you have questions or problems with the subscription service, please contact Subscriber Help. This service is provided to you at no charge by National Institute of Allergy and Infectious Diseases (NIAID).                             This email was sent to myhcistech.healthnews360@blogger.com using GovDelivery Communications Cloud on behalf of: National Institute of Allergy and Infectious Diseases · 5601 Fishers Lane · Bethesda, MD 20892 · 1-866-284-4107